Alterity Therapeutics discloses governance practices in August 2026 filing
The company's corporate governance statement details board composition, committee structures, and diversity metrics, with a note that the source document contains an apparent date typo for the Chair's start date.
Alterity Therapeutics Limited filed a Corporate Governance Statement dated August 28, 2026, covering the financial year ending 2026, as disclosed in a Form 6-K submitted to the SEC.
The statement addresses the company's compliance with the ASX Corporate Governance Council's Principles and Recommendations, 4th Edition. On board leadership, the filing states that the Chair of the Company from November 202, Mr Julian Babarczy, is an independent Director.1 The source text itself contains what appears to be a truncated or incomplete year reference, rendering the exact start date unclear from the document as filed.
The Board currently comprises five directors, and the Board comprises a total of 5 directors, of whom Mr Julian Babarczy, Ms Ann Cunningham and Mr Peter Marks are considered to be independent, meaning independent directors currently comprise the majority of the Board.1
On diversity, the company reported that it currently comprises 20% females on the Board, 0% among Executive Officers, 46% in senior management, and 54.5% of the total workforce.1 The Board stated that given the current small size of the Board and Company's operations, it does not presently intend to set measurable gender diversity objectives, but will reconsider the matter in due course following business growth.1
On committee structure, the filing notes that since November 2025, the Company had an Audit Committee comprised of three members, two of whom are independent Directors.1 Similarly, the Company had a Remuneration Committee for the past financial year, from November 2025, comprised of three members, two of whom are independent Directors.1
The document was signed by Julian Babarczy as Chairman on August 28, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.